News | November 16, 2006

Prostate Cancer Patients Report Fewer Side Effects with IMRT than with Brachytherapy

In one of the first studies to compare side effects of IMRT and permanent prostate brachytherapy (I-125) for treatment of low-risk prostate cancer, researchers say patients had fewer moderate and serious side effects when treated with IMRT.
"Both treatments demonstrated excellent PSA outcomes (biochemical control) after treatment," said Thomas N. Eade, MBChB, a fellow in the department of radiation oncology at Fox Chase Cancer Center. "The patients who received IMRT tended to be older, but even with that factor, IMRT was better tolerated."
The study included 374 patients with low-risk prostate cancers treated at Fox Chase with either IMRT (216 patients) or I-125 seed brachytherapy (158 patients). Patients who received neoadjuvant hormones were excluded from the study. The IMRT dose ranged from 74 to 78 Gy. The implant dose was 145 Gy. IMRT patients were an average of three years older (median age 67.6 years compared to 64.7 years).
Serious long-term side effects were significantly higher in the I-125 patients, including urethral stricture (narrowing) and catheterization. Catheterization within the first three months was required in three of the IMRT patients and 11 of the I-125 patients. Only one IMRT patient and seven of the implant patients required catheterization more than three months after completing treatment.
"This study shows men treated with brachytherapy have an increased risk of long-term side effects with brachytherapy as compared to IMRT," Eade said. "Advances in technologies will continue to improve outcomes for both treatment modalities, but for now IMRT delivers excellent cancer control with fewer long-term problems."

Related Content

CDN to Integrate Advanced Cardiac Imaging Tools From DiA Imaging Analysis
Technology | Advanced Visualization | August 10, 2017
August 10, 2017 — CDN recently announced a new partnership agreement with DiA Imaging Analysis Ltd., makers of next-g
Fujifilm Launches Synapse PACS Version 5
Technology | PACS | August 03, 2017
August 3, 2017 – Fujifilm Medical Systems U.S.A. Inc.
Agfa Receives FDA 510(k) for Xtend Functionalities on Xero Universal Viewer
Technology | Remote Viewing Systems | July 27, 2017
Agfa HealthCare announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Xero Xtend...
Amsterdam University Hospital Brings Sectra Education Portal Online
News | PACS Accessories | July 26, 2017
International medical imaging IT and cybersecurity company Sectra’s solution for medical education and clinical...
News | Enterprise Imaging | July 24, 2017
July 24, 2017 — Insignia Medical Systems has been selected to supply three National Health Service (NHS) Trusts worki
TomTec Unveils TomTec Zero Cardiovascular Viewing Software
Technology | Remote Viewing Systems | July 24, 2017
July 24, 2017 — TomTec Zero is the latest addition to the TomTec portfolio.
Philips Receives FDA 510(k) Clearance for IntelliSpace Portal 9.0
Technology | Advanced Visualization | June 29, 2017
Philips announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market...
RamSoft Partners With Gamel to Enhance Patient Care in Peruvian Market
News | PACS | June 23, 2017
RamSoft announced a new partnership with Peru-based medical imaging equipment provider, Gamel. With RamSoft’s...
Fujifilm Exhibits Suite of Enterprise Imaging Solutions at SIIM 2017
News | Enterprise Imaging | June 19, 2017
Fujifilm Medical Systems U.S.A. Inc. presented its comprehensive Synapse Enterprise Imaging portfolio at the 2017...
Vital Images to Address Specialized Workflow and Efficiency Challenges at SIIM 2017
News | Enterprise Imaging | June 01, 2017
An industry expert from Vital Images, Inc. (Vital) is participating in a discussion with the healthcare community on...
Overlay Init